macitentan 10 mg Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Actelion (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadHIV Infection

I am/have/hadatrial septal defect

I am/have/hadpatent ductus arteriosus

I am/have/hadventricular septal defect

I am/have/hadright heart catheterization

I am/have/hadhemodynamic evaluation

I am/have/hadseptal defect

I am/have/hadleft ventricular end-diastolic pressure

I am/have/hadhypertension

I am/have/hadventricular septal defects

I am/have/hadheart disease

I am/have/hadconnective tissue disease

added new label for I am/have/had

more

I am looking for

I am looking formacitentan

I am looking formacitentan 10 mg

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

atrial septal defect

heart disease

macitentan

patent ductus arteriosus

ventricular septal defect

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.